Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence

1 Apr 2019

Abstract excerpt

Abstract: The development of deep-sequencing methods is now unveiling a new landscape of previously undetected gene fusion across different tumor types. Chromosomal translocation involving the NTRK gene family occur across a wide range of cancers in both children and adults. Preclinical studies have demonstrated that chimeric proteins encoded by NTRK rearrangements have oncogenic properties and drive constitutive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to HER2/EGFR in Cancer Research
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31118670
DOI: 10.2147/ott.s177051

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidencePMID 31118670Read ↗

Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusionSemantic proximity Read ↗

Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancersSemantic proximity Read ↗

Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion CancerSemantic proximity Read ↗

TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults.Semantic proximity Read ↗

Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins.Semantic proximity Read ↗

TRK Inhibition: A New Tumor-Agnostic Treatment StrategySemantic proximity Read ↗

Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinibSemantic proximity Read ↗

Larotrectinib for the treatment of TRK fusion solid tumorsSemantic proximity Read ↗

Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancerSemantic proximity Read ↗

Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With NTRK Gene FusionSemantic proximity Read ↗

Targeting TRK: A Fast Tracked Application of Precision Oncology and Future DirectionsSemantic proximity Read ↗

Safety of current treatment options for NTRK fusion-positive cancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.